American Diabetes Association
Browse
Supplementary_material__.pdf (728.12 kB)

Association of body weight time in target range with the risk of kidney outcomes in patients with overweight/obesity and type 2 diabetes mellitus

Download (728.12 kB)
figure
posted on 2023-12-11, 17:00 authored by Cheng Zu, Mengyi Liu, Xinyue Su, Yuanxiu Wei, Qiguo Meng, Chengzhang Liu, Ziliang Ye, Xiaoqin Gan, Yuanyuan Zhang, Panpan He, Chun Zhou, Fan Fan Hou, Xianhui Qin

Objective: We aimed to assess the relationship of body weight time in target range (TTR) with composite kidney outcome in people with overweight/obesity and type 2 diabetes mellitus (T2DM).

Research Design and Methods: 3,601 participants with baseline estimated glomerular filtration rate (eGFR) ≥60mL/min/1.73 m2 from the Look AHEAD (Action for Health in Diabetes) trial were included. Body weight TTR was defined as the proportion of time during the first 4 years that body weight was within the weight loss target (a weight loss of at least 7% from baseline). The primary outcome was composite kidney outcome, defined as eGFR decline at least 30% from baseline and to a level of less than 60 mL/min/1.73 m2 at follow-up visit, or end-stage kidney disease.

Results: During a median follow-up of 8.0 years, 435 cases of composite kidney outcome were documented. Body weight TTR during the first 4 years was inversely associated with the subsequent risk of composite kidney outcome (Per SD increment; adjusted HR:0.81, 95%CI: 0.70-0.93). Accordingly, the adjusted HRs (95% CI) of composite kidney outcome were 1.00 (reference), 0.73 (0.54-1.00), 0.71 (0.52-0.99), and 0.54 (0.36-0.80) for participants with body weight TTR of 0%, >0% to <29.9%, 29.9% to <69.7%, and 69.7% to <100%, respectively. Similar results were found for a doubling of urine albumin-to-creatinine ratio (secondary outcome).

Conclusions: A higher body weight TTR, with a weight loss target of losing at least 7% of initial weight, was associated with a lower risk of kidney outcomes in participants with overweight/obesity and T2DM.

Funding

This study was supported by the National Key Research and Development Program (2022YFC2009600, 2022YFC2009605 to XHQ), the National Natural Science Foundation of China (81973133 to XHQ), the National Natural Science Foundation of China (Key Program) (82030022 to FFH); the Program of Introducing Talents of Discipline to Universities, 111 Plan (D18005 to FFH); Guangdong Provincial Clinical Research Center for Kidney Disease (2020B1111170013 to FFH); Key Technologies R&D Program of Guangdong Province (2023B1111030004 to FFH).

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC